These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28846488)

  • 1. Circulating Tumor DNA: Measurement and Clinical Utility.
    Donaldson J; Park BH
    Annu Rev Med; 2018 Jan; 69():223-234. PubMed ID: 28846488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid Biopsy and Lung Cancer.
    Pisapia P; Malapelle U; Troncone G
    Acta Cytol; 2019; 63(6):489-496. PubMed ID: 30566947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing Ultrasensitive Library-Aliquot-Based Droplet Digital PCR for Detecting T790M in Plasma-Circulating Tumor DNA of Non-small-Cell-Lung-Cancer Patients.
    Yang K; Li J; Zhao J; Ren P; Wang Z; Wei B; Dong B; Sun R; Wang X; Groen HJM; Ma J; Guo Y
    Anal Chem; 2018 Oct; 90(19):11203-11209. PubMed ID: 30156405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA testing in advanced non-small cell lung cancer.
    Moding EJ; Diehn M; Wakelee HA
    Lung Cancer; 2018 May; 119():42-47. PubMed ID: 29656751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
    Arriola E; Paredes-Lario A; García-Gomez R; Diz-Tain P; Constenla M; García-Girón C; Márquez G; Reck M; López-Vivanco G
    Clin Transl Oncol; 2018 Oct; 20(10):1261-1267. PubMed ID: 29623586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 7. The Role of Circulating Tumor DNA in Lung Cancer: Mutational Analysis, Diagnosis, and Surveillance Now and into the Future.
    Scilla KA; Rolfo C
    Curr Treat Options Oncol; 2019 Jun; 20(7):61. PubMed ID: 31203467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.
    Duffy MJ
    Tumour Biol; 2024; 46(s1):S283-S295. PubMed ID: 37270828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
    Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
    Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of circulating tumor DNA (ctDNA) by digital droplet polymerase chain reaction (dd-PCR) in liquid biopsies.
    Valpione S; Campana L
    Methods Enzymol; 2019; 629():1-15. PubMed ID: 31727235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive detection of actionable mutations in advanced non-small-cell lung cancer using targeted sequencing of circulating tumor DNA.
    Sim WC; Loh CH; Toh GL; Lim CW; Chopra A; Chang AYC; Goh LL
    Lung Cancer; 2018 Oct; 124():154-159. PubMed ID: 30268455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
    Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
    Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer.
    Yang X; Zhuo M; Ye X; Bai H; Wang Z; Sun Y; Zhao J; An T; Duan J; Wu M; Wang J
    Oncotarget; 2016 Apr; 7(15):20810-24. PubMed ID: 26989078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Color Crystal Digital PCR
    Madic J; Jovelet C; Dehri I; Mallory AC
    Methods Mol Biol; 2021; 2279():127-144. PubMed ID: 33683690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic Treatment Stratification Using ctDNA.
    Vidal J; Taus A; Montagut C
    Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Circulating Tumor DNA.
    Mithraprabhu S; Spencer A
    Methods Mol Biol; 2018; 1792():129-145. PubMed ID: 29797256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer.
    Chen K; Zhang J; Guan T; Yang F; Lou F; Chen W; Zhao M; Zhang J; Chen S; Wang J
    J Thorac Cardiovasc Surg; 2017 Sep; 154(3):1123-1131.e2. PubMed ID: 28625771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsy Promotes Non-Small Cell Lung Cancer Precision Therapy.
    Lu J; Han B
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818801809. PubMed ID: 30244652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.